Study | van Dijken, et al3 | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Publish yr | 2011 | ||||||||||||
Study design | Observational | ||||||||||||
Sex | F | F | F | F | F | F | F | F | F | F | M | M | M |
Age at IBD onset, yrs | 8 | 13.1 | 12.7 | 33.5 | 26.4 | 17.6 | 11.7 | 8.4 | 15.3 | 10.3 | 8.3 | 12.5 | 10 |
Underlying disease | Poly JIA | Oligo JIA | Oligo JIA | Poly JIA | Systemic JIA | ERA JIA | Oligo JIA | ERA JIA | Systemic JIA | Poly JIA | Oligo JIA | Oligo JIA | Poly JIA |
Age at rheumatic disease onset, yrs | 1.6 | 1.9 | 3.3 | 16.8 | 14.1 | 8 | 6.7 | 3.3 | 5.8 | 5.8 | 1 | 11.4 | 7.08 |
Duration of ETN treatment, yrs | 5.9 | 1.3 | 4.8 | 1.5 | 0.7 | 0.8 | 1.3 | 1.1 | 3.6 | 2.5 | 0.3 | 0.1 | 1.3 |
Time from disease diagnosis to ETN start, yrs | 0.6 | 9.9 | 4.8 | 16.6 | 12 | 16.8 | 10.4 | 4.2 | 9.3 | 3.3 | 8.1 | 12.4 | 2.8 |
Time from ETN to IBD, yrs | 5.8 | 1.3 | 4.5 | 1.4 | 0.3 | 0.8 | 1.3 | 1 | 3 | 2.3 | 0.1 | 0 | 0.4 |
CD/UC | UC | CD | ID | CD | CD | CD | CD | UC | CD | CD | CD | CD | UC |
Biopsy | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y |
Concomitant treatment | None | None | Nons | PSL, CSA | PSL, CSA | ETN cont. | ADA | None | None | None | MTX, PSL | NSAID, omeprazole, PSL | NSAID |
Decrease in IBD symptoms | IBD improved | IBD improved | IBD improved | IBD improved | IBD improved | NS | NS | IBD improved | IBD improved | NS | IBD persisted | IBD improved | IBD improved |
IBD treatment after | IFX, ADA | MSZ, IFX, ADA | NS | ADA | IFX, SSZ | ETN, MTX, PSL, SSZ | ADA | IFX, BUD, MSZ | MSZ | PSL, ADA | PSL | IFX, BUD, MSZ | IFX |
IBD progression: penetrating, stricturing, inflammatory | NS | NS | Inflammatory | NS | NS | NS | NS | Inflammatory | NS | Inflammatory | Inflammatory | NS | Inflammatory |
IBD: inflammatory bowel disease; ETN: etanercept; CD: Crohn disease; UC: ulcerative colitis; NS: not specified; poly: polyarticular; JIA: juvenile idiopathic arthritis; oligo: oligoarticular; ERA: enthesitis-related arthritis; ID: undifferentiated IBD; PSL: prednisone; CSA: cyclosporine; ETN cont.: ETN continuous; ADA: adalimumab; MTX: methotrexate; NSAID: nonsteroidal antiinflammatory drugs; IFX: infliximab; MSZ: mesalazine; SSZ: sulfasalazine; BUD: budesonide.